Clinical trials: Recurrent Glioblastoma IDH Wildtype
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4)…
- Trial name
- GLIOMAX-101 (NCT07386002)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
Glioblastoma
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
- Trial name
- NCT03743662
- Testing
- Re-irradiation (RT), Bevacizumab, Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.
- Conditions
- Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastoma Multiforme, Adult
- Trial name
- NCT07668869
- Testing
- Tumor Treating Fields (TTFields), FET-PET-Guided Stereotactic Radiosurgery
- Where
- Poland
- Volunteers
- 92 people
- Sponsor
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
This phase I trial studies the side effects and best dose of Actimab-A when given together with cemiplimab (REGN2810) in treating patients with glioblastomas that have come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT07422363
- Testing
- Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.
- Trial name
- NCT07520214
- Testing
- mRNA vaccine: GV-907、GV-108
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Neurosurgical Institute
Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
The primary objective of this study is to evaluate the dosimetry, safety, and tolerability of the investigational radiopharmaceutical [177Lu]Lu-XT771 in patients with recurrent glioblastoma, an aggressive form of brain cancer.
- Conditions
- Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma, Glioblastoma (GBM), Recurrent Glioblastoma IDH Wildtype
- Trial name
- NCT07648823
- Testing
- [177Lu]Lu-XT771
- Where
- 2 sites in China
- Volunteers
- 5 people
- Sponsor
- Beijing Tiantan Hospital